Last 5,275 GBp
Change Today -40.00 / -0.75%
Volume 1.4M
SHP On Other Exchanges
Symbol
Exchange
SHP is not on other exchanges.
As of 11:35 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

shire plc (SHP) Snapshot

Open
5,340 GBp
Previous Close
5,315 GBp
Day High
5,340 GBp
Day Low
5,255 GBp
52 Week High
10/6/14 - 5,470 GBp
52 Week Low
04/14/14 - 2,827 GBp
Market Cap
31.6B
Average Volume 10 Days
1.4M
EPS TTM
5.60 GBp
Shares Outstanding
599.2M
EX-Date
03/12/15
P/E TM
14.6x
Dividend
14.75 GBp
Dividend Yield
0.24%
Current Stock Chart for SHIRE PLC (SHP)

shire plc (SHP) Details

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/ VENVANSE/ ELVANSE/ TYVENSE/ ELVANS E VUXEN/ADUVANZ; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides BUCCOLAM for epilepsy treatment; PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist that is used for the treatment of chronic constipation in women. In addition, it offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR and CINRYZE C1 esterase inhibitor for the treatment of hereditary angioedema. Further, the company provides FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; XAGRID that is used for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients; and PLENADREN for the treatment of adrenal insufficiency. Additionally, it licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. The company also focuses on the development of resources projects in various therapeutic areas, including rare diseases, neuroscience, ophthalmics, hematology, and gastrointestinal disorders; and early development projects primarily on rare diseases. Shire plc markets its products through wholesalers and pharmacies. The company has research collaboration with ArmaGen Technologies Inc., Santaris Pharma A/S, and Sangamo. Shire plc was founded in 1986 and is based in Dublin, Ireland.

5,016 Employees
Last Reported Date: 02/24/15
Founded in 1986

shire plc (SHP) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: $3.6M
Compensation as of Fiscal Year 2014.

shire plc (SHP) Key Developments

Investors Reportedly Eyes Stake In PTCT

PTC Therapeutics, Inc. (NasdaqGS:PTCT) is exploring a potential sale amid takeover interest from Shire plc (LSE:SHP) and BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), according to people familiar with the matter. PTCT is working with financial advisers as it weighs strategic alternatives, said the sources, who asked not to be named because the matter is private. Representatives for could not be reached for comment. Representatives for Shire and BioMarin declined to comment. Shire Plc could be interested in acquiring PTC Therapeutics to add to its portfolio of rare disease drugs, the sources added.

Shire plc Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Financial Guidance for the Year 2015; Announces Write Down of Assets for the Fourth Quarter of 2014

Shire plc announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net income of $2,172.3 million or 367.3 cents per diluted share and 1,101.9 cents per diluted ADS on total revenue of $1,576.1 million compared to net income of $64.0 million or 11.7 cents per diluted share and 35.1 cents per diluted ADS on total revenue of $1,326.0 million reported in the same period last year. Income from continuing operations, net of tax was $1,985.6 million or 335.7 cents per diluted share against $546.6 million or 93.4 cents per diluted share reported last year. Operating income from continuing operations was $481.2 million against $598.3 million reported last year. Income from continuing operations before income taxes and equity in earnings of equity method investees was $2,107.5 million against $585.9 million reported last year. Net cash provided by operating activities was $2,554.9 million against $610.3 million reported last year. Capital expenditure was $27.2 million against $46.7 million reported last year. Non GAAP EBITDA was $693.8 million against $548.7 million reported last year. Non GAAP Operating income from continuing operations was $655.5 million against $510.4 million reported last year. On a Non GAAP basis operating income grew 28% to $655 million against $510 million reported last year. Non GAAP diluted earnings per ADS increased 17% to $2.63 against $2.26 reported last year. For the year, the company reported net income of $3,405.5 million or 576.0 cents per diluted share and 1,728.0 cents per diluted ADS on total revenue of $6,022.1 million compared to net income of $665.1 million or 117.5 cents per diluted share and 352.5 cents per diluted ADS on total revenue of $4,934.3 million reported in the same period last year. Income from continuing operations, net of tax was $3,282.8 million or 555.2 cents per diluted share against $1,419.6 million or 245.3 cents per diluted share reported last year. Operating income from continuing operations was $1,698.0 million against $1,733.5 million reported last year. Income from continuing operations before income taxes and equity in earnings of equity method investees was $3,336.2 million against $1,693.6 million reported last year. Net cash provided by operating activities was $4,228.4 million against $1,463.0 million reported last year. Capital expenditure was $77.0 million against $157.0 million reported last year. Non GAAP EBITDA was $2,756.5 million against $1,987.3 million reported last year. Non GAAP Operating income from continuing operations was $2,593.0 million against $1,859.7 million reported last year. On a Non GAAP basis operating income grew strongly in 2014, up 39% to $2,593 million from $1,860 million reported last year. Non GAAP diluted earnings per ADS increased 38% to $10.60 against $7.66 reported last year. For the quarter, the company also reported write down of assets of $0.3 million compared to $50.4 million reported in the same period last year. Based on actual exchange rates, The company anticipates low-to-mid single digit product sales growth in 2015. Non GAAP gross margin is expected to be in line with 2014 margin of 85.8%. For 2015, The company expects effective tax rate on Non GAAP income to be in the range of 15-17%, before reverting to the 17-19% range in 2016 and beyond. Non GAAP diluted earnings per ADS growth is expected in the mid-single digits in 2015 (high single digit growth on a CER basis). Royalties and other revenues are expected to increase by 30% to 40% in 2015, as the company includes NPS's royalty streams for the first time.

Shire plc Announces David Stout to Step Down from the Board and the Committees, Effective from April 28, 2015

Shire plc announced that David Stout has informed the Board of his intention to step down from the Board and the Committees on which he serves with effect from the conclusion of the company's AGM on April 28, 2015. The advanced stage of the proposed combination with AbbVie in 2014 led Mr. Stout to consider other opportunities for 2015. Mr. Stout has been on the Shire Board since October 2009.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHP:LN 5,275.00 GBp -40.00

SHP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CSL Ltd A$92.24 AUD +1.78
Eisai Co Ltd ¥6,242 JPY -58.00
Hospira Inc $87.54 USD 0.00
Mylan Inc/PA $57.33 USD +0.08
UCB SA €68.35 EUR -1.26
View Industry Companies
 

Industry Analysis

SHP

Industry Average

Valuation SHP Industry Range
Price/Earnings 14.6x
Price/Sales 7.9x
Price/Book 5.5x
Price/Cash Flow 14.1x
TEV/Sales 8.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.